Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Arexvy (RSVPreF3 OA) Vaccine in Older Adults (AReSVi-006)
NCT04886596Phase 3Completed
- Sponsor
- GSK
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 17
01
Overview
A Phase 3 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV), sponsored by GSK. Started May 2021; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04886596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886596.